NeuroOne Medical Technologies (NASDAQ:NMTC) Issues Quarterly Earnings Results

NeuroOne Medical Technologies (NASDAQ:NMTC) announced its quarterly earnings data on Tuesday. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01, FiscalAI reports. The company had revenue of $2.89 million during the quarter, compared to the consensus estimate of $2.47 million. NeuroOne Medical Technologies had a negative return on equity of 125.10% and a negative net margin of 78.34%.

Here are the key takeaways from NeuroOne Medical Technologies’ conference call:

• Revenue guidance of at least $10.5 million for FY2026, a stated minimum 17% increase year‑over‑year, and management says the company is funded through fiscal 2026 (subject to hitting key milestones).
• The OneRF brain ablation system showed accelerating adoption — Q1 ablations were nearly half of all procedures since launch — and the company plans a registry with first patient enrollment targeted by the end of Q3.
• The OneRF trigeminal nerve system has FDA 510(k) clearance, completed a limited launch with nine patients at three centers who are reported pain‑free, and the limited launch is expected to finish by end of Q2 while strategic licensing discussions continue.
• Financials show a Q1 net loss of $1.4 million (vs. prior‑year income that included a $3 million license payment), no license revenue this quarter, and cash down to $3.6 million from $6.6 million, leaving a limited runway despite being “funded through fiscal 2026.”
• Pipeline progress accelerated — drug‑delivery devices are expected to be available for investigational/animal use in Q3 (about six months earlier than planned), animal studies for the percutaneous paddle electrode are starting soon, and basivertebral nerve work is advancing with advisory boards and partnership discussions.

NeuroOne Medical Technologies Price Performance

NMTC stock opened at $0.67 on Thursday. The company has a 50 day moving average price of $0.81 and a 200 day moving average price of $0.80. NeuroOne Medical Technologies has a fifty-two week low of $0.40 and a fifty-two week high of $1.18. The stock has a market capitalization of $33.59 million, a PE ratio of -3.92 and a beta of 0.71.

Hedge Funds Weigh In On NeuroOne Medical Technologies

Several hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. bought a new stake in NeuroOne Medical Technologies during the 1st quarter worth about $84,000. Warberg Asset Management LLC bought a new stake in NeuroOne Medical Technologies in the second quarter valued at approximately $27,000. XTX Topco Ltd acquired a new stake in NeuroOne Medical Technologies during the second quarter worth approximately $51,000. Sio Capital Management LLC bought a new position in NeuroOne Medical Technologies during the 2nd quarter worth $2,390,000. Finally, Focus Financial Network Inc. acquired a new position in NeuroOne Medical Technologies in the 3rd quarter valued at $31,000. Institutional investors own 16.07% of the company’s stock.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $2.23.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.